Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 11/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10327319 | 0.92 | RAF1 (0.45) | LMNALCKKDRTHRBTRPV4 | |
| SCHEMBL12946857 | 0.90 | TRPV4 (0.44) | LMNALCKKDRTHRBTRPV4 | |
| SCHEMBL10327385 | 0.88 | LMNA (0.46) | LMNATHRBTRPV4EPHX2KMT2A | |
| SCHEMBL10327373 | 0.86 | LMNA (0.46) | LMNATHRBTRPV4EPHX2KMT2A | |
| SCHEMBL10180583 | 0.86 | TRPV4 (0.42) | LMNALCKKDRTHRBTRPV4 | |
| SCHEMBL12946985 | 0.85 | MAPK8 (0.45) | LMNALCKKDRTHRBTRPV4 | |
| SCHEMBL12946845 | 0.81 | TRPV4 (0.44) | LMNATHRBTRPV4EPHX2KMT2A | |
| SCHEMBL10327088 | 0.81 | SMN1; SMN2 (0.47) | LMNAKMT2A | |
| SCHEMBL10180028 | 0.80 | MAPK8 (0.45) | LMNATHRBTRPV4EPHX2KMT2A | |
| SCHEMBL10327259 | 0.79 | TRPV4 (0.49) | LMNATRPV4EPHX2KMT2ACASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678168-B1 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2012-07-11 | — | — | EP | disclosed |